No abstract available
Publication types
-
Case Reports
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Aged
-
Antineoplastic Agents / pharmacology
-
Antineoplastic Agents / therapeutic use*
-
Arginine
-
Back
-
Cell Survival / drug effects
-
Enzyme Activation
-
Extracellular Signal-Regulated MAP Kinases / drug effects
-
Female
-
Humans
-
Imidazoles / administration & dosage
-
Imidazoles / pharmacology
-
Indoles / administration & dosage
-
Indoles / pharmacology
-
Leucine
-
Lung Neoplasms / drug therapy*
-
Lung Neoplasms / genetics
-
Lung Neoplasms / secondary
-
MAP Kinase Signaling System / drug effects*
-
Melanoma / drug therapy*
-
Melanoma / genetics
-
Niacinamide / administration & dosage
-
Niacinamide / analogs & derivatives
-
Niacinamide / pharmacology
-
Oximes / administration & dosage
-
Oximes / pharmacology
-
Phenylurea Compounds / administration & dosage
-
Phenylurea Compounds / pharmacology
-
Point Mutation*
-
Proto-Oncogene Proteins B-raf / antagonists & inhibitors*
-
Proto-Oncogene Proteins B-raf / genetics*
-
Skin Neoplasms / drug therapy*
-
Skin Neoplasms / genetics
-
Sorafenib
-
Sulfonamides / administration & dosage
-
Sulfonamides / pharmacology
-
Vemurafenib
Substances
-
Antineoplastic Agents
-
Imidazoles
-
Indoles
-
Oximes
-
Phenylurea Compounds
-
Sulfonamides
-
Vemurafenib
-
Niacinamide
-
Arginine
-
Sorafenib
-
BRAF protein, human
-
Proto-Oncogene Proteins B-raf
-
Extracellular Signal-Regulated MAP Kinases
-
Leucine
-
dabrafenib